A Randomized, Phase 1, Three-Period, Placebo- and Positive-Controlled, Double-Blind, Crossover Study to Assess the Electrophysiological Effects of Exenatide at Therapeutic and Supratherapeutic Concentrations on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects.

Trial Profile

A Randomized, Phase 1, Three-Period, Placebo- and Positive-Controlled, Double-Blind, Crossover Study to Assess the Electrophysiological Effects of Exenatide at Therapeutic and Supratherapeutic Concentrations on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2014

At a glance

  • Drugs Exenatide (Primary) ; Moxifloxacin
  • Indications Bacterial infections; Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Registrational
  • Sponsors AstraZeneca; Bristol-Myers Squibb
  • Most Recent Events

    • 11 Jul 2011 Planned number of patients changed from 100 to 75.
    • 07 Jul 2011 Planned end date changed from Jun 2011 to Aug 2011 as reported by ClinicalTrials.gov.
    • 07 Jul 2011 Primary endpoint 'QT-interval' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top